STOCK TITAN

NYSE - NYSE STOCK NEWS

Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for patients with advanced cancers. This news hub provides investors and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic partnerships.

Access authoritative information about Actinium’s Antibody Radiation Conjugate (ARC) platform, including progress on lead candidates Iomab-B for bone marrow transplant conditioning and Iomab-ACT for CAR-T therapy preparation. Our curated news collection features press releases on trial results, FDA communications, and collaborations with leading cancer research centers.

Key updates include phase 3 trial data for hematologic malignancies, manufacturing advancements for radiotherapy agents, and scientific presentations at major oncology conferences. All content is vetted for accuracy and relevance to treatment innovation in cellular therapies.

Bookmark this page for streamlined tracking of Actinium’s progress in redefining cancer treatment paradigms through precision radiotherapy. Verify time-sensitive updates directly through SEC filings and official company communications.

Rhea-AI Summary
Actinium Pharmaceuticals has appointed Lynn Bodarky as Chief Business Officer to lead the company's business development, licensing, and collaboration activities. Ms. Bodarky brings over 25 years of experience in business development and licensing, having executed transactions totaling over $5 billion in value across oncology, autoimmune, and neurological indications. Actinium is a leader in the development of targeted radiotherapies, with a pipeline of highly differentiated therapies and expertise in alpha-emitter payload Actinium-225. The company has positive Phase 3 data for Iomab-B, a CRADA with the NCI, an NIH grant for Iomab-ACT, and novel preclinical solid tumor data. Actinium aims to leverage Ms. Bodarky's extensive experience to bring their radiotherapeutics to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, from November 6 - 8, 2023 in Munich, Germany. Actinium is developing targeted radiotherapies, including Iomab-B for bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial. Actinium is also advancing other clinical-stage targeted radiotherapeutics and solid tumor programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Actinium Pharmaceuticals announced that three abstracts detailing results from the Phase 3 SIERRA trial of Iomab-B in relapsed or refractory acute myeloid leukemia (AML) patients have been accepted for presentation at the ASH conference. The trial showed that AML patients with a TP53 mutation who received Iomab-B and a bone marrow transplant had a median overall survival of 5.49 months compared to 1.66 months in patients who did not receive Iomab-B. Iomab-B also demonstrated similar overall survival outcomes in TP53 negative patients. 24% of patients enrolled in the trial had a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Vicarious Surgical to report Q3 2023 financial results on November 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Actinium Pharmaceuticals details abstract accepted for poster presentation at SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Actinium Pharmaceuticals details three abstracts accepted for poster presentation at SOHO 2023 Annual Meeting, showcasing positive results of their treatments for AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Riskified Ltd. (NYSE: RSKD) will release second quarter 2023 financial results on August 15, 2023. A conference call and webcast will be held at 8:30 a.m. ET to discuss the company's business and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Argent Trust Company, as Trustee of the Hugoton Royalty Trust, announced a cash distribution of $0.010003 per unit payable on June 14, 2023. Underlying gas and oil sales volumes for the current month were 662,000 Mcf and 13,000 Bbls, with average prices of $4.43 per Mcf and $71.76 per Bbl.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
NYSE

NYSE:NYSE

NYSE Rankings

NYSE Stock Data